CE Marking for Momentum Biosciences’ Innovative Blood Culture Test
Momentum Bioscience Ltd is pleased to announce that it has CE marked Cognitor® Minus, the first in a range of products for the hospital microbiology laboratory utilising ETGA®. ETGA® is a novel technology for the rapid, universal detection of viable bacteria & fungi.
Cognitor® products are designed for the rapid detection/exclusion of infection, assisting clinicians with antibiotic stewardship, improved patient outcomes and treatment costs.
Patients at risk of sepsis are routinely placed on broad-spectrum intravenous antibiotics until definitive information is available from blood culture samples sent to the hospital laboratory. Up to 90% of blood cultures are negative but take 5 days to be confirmed as such. Cognitor® Minus gives a confirmed negative result, direct from blood culture, the day following sample receipt by the laboratory with a negative predictive value (NPV) of 99.5%.
Cognitor® Minus will have its formal launch at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Copenhagen, Denmark on 25th - 28th April 2015.
Note: This product is currently not available for sale in the USA
Tags: Blood Culture, Sepsis
Date Published: April 27, 2015
Source article link: Momentum BioScience » company contact details
bioMérieux and DIAGNOSTICS IS POWER at ECCMID 2018
Biospectrix™ Identifies Blood Pathogens Without Culture
LiDia® BSI Test: Detection of Pathogens in Clinical Whole Blood Samples
Bruker Introduces Novel PCR Assays for Aspergillosis and Carbapenem Resistance
FDA Clearance for BacT/ALERT® VIRTUO™ Fully Automated Blood Culture System